Melody Smith, MD, examines the role of antibiotic exposure after CAR-T infusion on survival outcomes, at the IMS/AACR joint session. #IMS26

Abstract Sessions begin at 5:00 PM. Join us in Hall 5 for Abstract Session 5 or Lomond Auditorium for Abstract Session 6. #IMS26

At 4:00 PM in Hall 5: IMS/EHA Session. #IMS26

CAR-T recipients who develop movement and neurocognitive toxicities had increased inflammatory signaling at baseline and higher apheresis CD4/CD8 ratio --- Theresia Akhlaghi, MD. #IMS26

Jeffrey Matous, MD, shares updates on the TRIlogy-1 trial of ramantamig, a BCMA & GPRC5d trispecific antibody. Response was sustained in pts who switched to Q8W dosing; 2-year PFS was >80% in pts with BCMA/GPRC5d-naïve TCE RRMM. #IMS26

Read this Blood Cancer Discovery article: “Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma” in advance of the IMS/AACR session on CAR T cells and the microbiome. #IMS26 buff.ly/G4hrfKw

At 2:30 PM in Hall 5: IMS/AACR Session. #IMS26

Don’t miss the IMS/AACR session on CAR T cells and the microbiome today at 2:30 PM, cochaired by Blood Cancer Discovery Editor-in-Chief Kenneth C. Anderson. #IMS26

Luca Bertamini, MD, spoke about the potential of circulating tumor cells in assessing disease burden, refining prognostication & risk stratification and tailoring treatment. #IMS26

We should prioritize quality of life (QoL) as an endpoint in MM clinical trials, especially in high-risk patients --- Karthik Ramasamy, MD, PhD. He presented QoL data from the RADAR trial in newly diagnosed pts w/ ultra high-risk MM. #IMS26

Congratulations to Sagar Lonial MD, FACP, FASCO, the recipient of the Waldenström Lifetime Achievement Award at #IMS26.

Congratulations to Nizar J Bahlis, MD, the recipient of the Ken Anderson Basic and Translational Research Award at #IMS26.

Congratulations to Sonja Zweegman, MD, PhD, the recipient of the Bart Barlogie Clinical Investigator Award at #IMS26.

Read this recent Blood Cancer Discovery article by #IMS26 speaker Maximilian Merz, “Outcomes of CAR T-cell therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.” buff.ly/9y7L7QB

Whole genome sequencing, rather than targeted or bespoke panel-based sequencing assays, has better sensitivity for detecting cell-free DNA shed by MM cells in serum --- Suzanne Trudel, MD #IMS26

Mass spectrometry (MS) extends observable disease trajectory in both directions, Noemi Puig, MD, PhD, said. “Serum MS and bone marrow MRD are often hierarchical rather than complementary, with bone marrow MRD being more informative.” #IMS26

Read this Blood Cancer Discovery research brief by #IMS26 speaker Madhav Dhodapkar, “Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.” buff.ly/cuqUcCZ

Industry Symposium focused on barriers/challenges and discussed potential solutions, practical operational frameworks for coordinated outpatient delivery of BCMA bispecific antibody therapy in myeloma practice. #IMS26

Read this Blood Cancer Discovery research brief by #IMS26 speaker Bruno Paiva, “Genetic Evidence against Clonotypic B Lymphocytes as a Reservoir for Plasma-cell Cancers.” buff.ly/IaYgkNp

At 1:00 PM in Hall 5: Industry Symposium Supported by Johnson & Johnson. #IMS26